AI-generated summary
The authors ran a double-blind randomized trial of 830-nm gallium arsenide aluminum laser therapy in 64 patients with chronic neck myofascial pain syndrome. Both the laser group and the switched-off placebo group improved on pain, range of motion and disability measures, but the authors report no significant difference between the groups. They note they cannot rule out benefit with a different laser regimen.
- Participants
- 64
- Who or what was studied
- Patients with chronic cervical myofascial pain syndrome (neck)
- Wavelengths
- 830 nm
- Limits stated in the abstract
- The authors state that the laser showed no superiority over placebo and that only one treatment regimen was tested.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Placebo-controlled, Low-level laser therapy, Randomized controlled trial. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.